Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
42
CGTX Quote, Financials, Valuation and Earnings
Last price:
$1.45
Seasonality move
:
24.89%
Day range:
$1.40 - $1.47
52-week range:
$0.22 - $3.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.53x
Volume:
425.2K
Avg. volume:
976.6K
1-year change:
125.31%
Market cap:
$128.9M
Revenue:
--
EPS (TTM):
-$0.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CGTX
Cognition Therapeutics, Inc.
|
-- | -$0.09 | -- | -54.12% | $3.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CGTX
Cognition Therapeutics, Inc.
|
$1.46 | $3.50 | $128.9M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CGTX
Cognition Therapeutics, Inc.
|
1.03% | 0.370 | 0.32% | 5.98x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CGTX
Cognition Therapeutics, Inc.
|
-$61K | -$6.4M | -152.93% | -157.12% | -- | -$5.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Cognition Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CGTX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cognition Therapeutics, Inc.'s net margin of -255.85%. Cognition Therapeutics, Inc.'s return on equity of -157.12% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics, Inc.-- -$0.06 $36.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CGTX or NBY?
Cognition Therapeutics, Inc. has a consensus price target of $3.50, signalling upside risk potential of 139.73%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Cognition Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cognition Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics, Inc.4 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CGTX or NBY More Risky?
Cognition Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CGTX or NBY?
Cognition Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cognition Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or NBY?
Cognition Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cognition Therapeutics, Inc.'s net income of -$4.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cognition Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics, Inc.-- -- -- -$4.9M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns CGTX or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Cognition Therapeutics, Inc.'s net margin of --. Cognition Therapeutics, Inc.'s return on equity of -157.12% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics, Inc.-- -$0.06 $36.9M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About CGTX or NNVC?
Cognition Therapeutics, Inc. has a consensus price target of $3.50, signalling upside risk potential of 139.73%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than Cognition Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Cognition Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics, Inc.4 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is CGTX or NNVC More Risky?
Cognition Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock CGTX or NNVC?
Cognition Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or NNVC?
Cognition Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Cognition Therapeutics, Inc.'s net income of -$4.9M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Cognition Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics, Inc.-- -- -- -$4.9M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns CGTX or OGEN?
Oragenics, Inc. has a net margin of -- compared to Cognition Therapeutics, Inc.'s net margin of --. Cognition Therapeutics, Inc.'s return on equity of -157.12% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics, Inc.-- -$0.06 $36.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CGTX or OGEN?
Cognition Therapeutics, Inc. has a consensus price target of $3.50, signalling upside risk potential of 139.73%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Cognition Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Cognition Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics, Inc.4 0 0 OGENOragenics, Inc.1 0 0 -
Is CGTX or OGEN More Risky?
Cognition Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CGTX or OGEN?
Cognition Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or OGEN?
Cognition Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Cognition Therapeutics, Inc.'s net income of -$4.9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Cognition Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics, Inc.-- -- -- -$4.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CGTX or PTN?
Palatin Technologies has a net margin of -- compared to Cognition Therapeutics, Inc.'s net margin of --. Cognition Therapeutics, Inc.'s return on equity of -157.12% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics, Inc.-- -$0.06 $36.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CGTX or PTN?
Cognition Therapeutics, Inc. has a consensus price target of $3.50, signalling upside risk potential of 139.73%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Cognition Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Cognition Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics, Inc.4 0 0 PTNPalatin Technologies0 0 0 -
Is CGTX or PTN More Risky?
Cognition Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CGTX or PTN?
Cognition Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or PTN?
Cognition Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Cognition Therapeutics, Inc.'s net income of -$4.9M is higher than Palatin Technologies's net income of --. Notably, Cognition Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics, Inc.-- -- -- -$4.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CGTX or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Cognition Therapeutics, Inc.'s net margin of --. Cognition Therapeutics, Inc.'s return on equity of -157.12% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics, Inc.-- -$0.06 $36.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CGTX or TOVX?
Cognition Therapeutics, Inc. has a consensus price target of $3.50, signalling upside risk potential of 139.73%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Cognition Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Cognition Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics, Inc.4 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CGTX or TOVX More Risky?
Cognition Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CGTX or TOVX?
Cognition Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or TOVX?
Cognition Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Cognition Therapeutics, Inc.'s net income of -$4.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Cognition Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics, Inc.-- -- -- -$4.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 3.73% over the past day.
Buy
60
AAOI alert for Dec 26
Applied Optoelectronics, Inc. [AAOI] is down 9.39% over the past day.
